Intrinsic Value of S&P & Nasdaq Contact Us

Kane Biotech Inc. KNBIF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
54/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Kane Biotech Inc. (KNBIF) is a Biotechnology company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $2M, +422.8%/yr average growth. Net income is $6M, growing at +69.1%/yr. Net profit margin is 293% (strong). Gross margin is 41.9% (+6.5 pp trend).

Balance sheet: total debt is $2M with negative equity of -$2M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.43 (tight liquidity). Debt-to-assets is 87.2%. Total assets: $2M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 0/100 (Fail), Moat 43/100 (Fail), Future ?/100 (Fail), Income 100/100 (Pass).

KNBIF SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Stock Chart & Stats

Market Data
52-Week Range0.02031-0.0704
Volume50K
Avg Volume (30D)12.87K
Market Cap$3.55M
Beta (1Y)0.24
Share Statistics
EPS (TTM)-0.02
Shares Outstanding$133.91M
IPO Date2007-08-07
CEORobert Huizinga
Financial Highlights & Ratios
Revenue (TTM)$2.08M
Gross Profit$872.1K
EBITDA$-3.71M
Net Income$6.1M
Operating Income$-3.92M
Total Cash$358.81K
Total Debt$2.18M
Net Debt$1.82M
Total Assets$2.49M
Price / Earnings (P/E)-0.9
Price / Sales (P/S)1.7
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA4838092084

Price Chart

KNBIF
Kane Biotech Inc.  ·  Other OTC
Healthcare • Biotechnology
0.02 52WK RANGE 0.07
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message